Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2014

View Archived Issues

Kinetic analysis of the new PET ligand [11C]Lu-AE-92686

ProteoTech given FDA orphan drug status for AL amyloidosis candidate

RetroSense Therapeutics gene therapy gains FDA orphan drug status for retinitis pigmentosa

RadioMedix and Viewpoint Molecular Targeting receive grant for melanoma theranostics

iBio expands collaboration with Novici Biotech

Bavarian Nordic expands collaboration with Janssen on MVA-BN

GlaxoSmithKline reviews pipeline progress of third quarter 2014

VSV-ZEBOV Ebola vaccine candidate begins phase I study at NIAID

Serum bilirubin: a prognostic marker in primary sclerosing cholangitis

Phase III data from GEMINI trials presented for vedolizumab

First-in-human results presented for radiolabeled antibody [68Ga]ABY-025

Vitae Pharmaceuticals reports phase I results for BI-1181181/VTP-37948

The Walter Reed Army Institute discloses new agents for malaria

Novel GPR120 modulators divulged by Bristol-Myers Squibb

SHIELD 4 phase III data presented for vercirnon in patients with Crohn's disease

Sutro Biopharma and Celgene expand agreement for ADCs in immuno-oncology

U.S. group designs novel agents for depression and Parkinson's disease

Sumitomo Dainippon Pharma discloses novel RIO kinase 2 inhibitors

Bristol-Myers Squibb prepares novel agents for HIV infection

Stellar Biotechnologies agrees to supply KLH for BiovaxID

CTI BioPharma acquires worldwide rights to phase II cancer agent tosedostat

FDA sends CRL to Lundbeck regarding intravenous carbamazepine NDA

FDA approves Baxter's Obizur for acquired hemophilia A

CHMP adopts positive opinion for oxycodone/naloxone in RLS

CHMP recommends expanding approval of enzalutamide

EMA committee backs approval of olaparib in BRCA-mutated ovarian cancer

EMA recommends that Clinuvel's Scenesse be approved for EPP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...